Lusvertikimab selectively inhibits IL-7 but not the thymic stromal lymphopoietin (TSLP) axis, Bourreille told attendees. A ...

Discover a study that has revealed a new potential mechanism of understanding inflammation in ulcerative colitis.

New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable ...

Microbiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal barrierData presented at Digestive Disease Week in San ...

CHARLOTTE, N.C. -- Wide receiver Hunter Renfrow dropped from 185 pounds to 150 pounds last year while being treated for ...

Proctitis causes rectal discomfort and bleeding. Learn what triggers it, how it's diagnosed, and which treatments actually ...

Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC ...

Johnson & Johnson (J&J) has shared positive long-term results from a phase 3 trial of its dual-acting IL-23 inhibitor Tremfya ...

The primary endpoint of comprehensive disease control was defined as a combination of clinical remission (CDAI under 150; ...

Guselkumab significantly improves clinical remission rates in patients with active ulcerative colitis, according to phase 3 data.

The company noted that TREMFYA is positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks.

CHARLOTTE, N.C. -- Wide receiver Hunter Renfrow dropped from 185 pounds to 150 pounds last year while being treated for ulcerative colitis, which played a big role in his decision to step away ...